Mitoxantrone information

Mitoxantrone
Clinical data
Trade names	Novantrone
AHFS/Drugs.com	Monograph
MedlinePlus	a608019
Routes of; administration	Mainly intravenous
ATC code	L01DB07 (WHO) ;
Legal status
Legal status	US: WARNING; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	n/a
Protein binding	78%
Metabolism	Hepatic (CYP2E1)
Elimination half-life	75 hours
Excretion	Renal
Identifiers
	IUPAC name 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino); ethylamino]-anthracene-9,10-dione;
CAS Number	65271-80-9 ;
PubChem CID	4212;
IUPHAR/BPS	7242;
DrugBank	DB01204 ;
ChemSpider	4067 ;
UNII	BZ114NVM5P;
KEGG	D08224 ;
ChEBI	CHEBI:50729 ;
ChEMBL	ChEMBL58 ;
PDB ligand	MIX (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID4046947 ;
Chemical and physical data
Formula	C22H28N4O6
Molar mass	444.488 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2c1c(c(NCCNCCO)ccc1NCCNCCO)C(=O)c3c2c(O)ccc3O;
	InChI InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2 ; Key:KKZJGLLVHKMTCM-UHFFFAOYSA-N ;
	(verify)

Mitoxantrone (INN, BAN, USAN; also known as Mitozantrone in Australia; trade name Novantrone) is an anthracenedione antineoplastic agent.

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

and 23 Related for: Mitoxantrone information